Home › Companies › NVCT

Nuvectis Pharma

NVCT Lead: Phase 1 4 Biotech Distilled articles ↓

Oncology Small Molecule

Most recent annual filing: 2026-02-11

Pipeline (3 active programs)

NXP900

Small Molecule Target: SRC, YES1

Non-Small Cell Lung Cancer Phase 1 oral University of Edinburgh
Renal Cell Carcinoma Phase 1 oral University of Edinburgh
Mesothelioma Phase 1 oral University of Edinburgh

Discontinued (1)

NXP800 — Ovarian Cancer · following the completion of a Phase 1b clinical study, we decided to cease clinical development of NXP800

Biotech Distilled coverage (4)

2026-06-30 UPDATE: Nuvectis Pharma (NVCT) - The Financing Print I Was Waiting For
2026-06-30 UPDATE: Nuvectis Pharma (NVCT) - The Deal Priced Below My Yellow Flag
2026-06-23 UPDATE: Nuvectis Pharma (NVCT) - The One-Asset Company Just Bought Two More
2026-06-02 Nuvectis Pharma (NVCT) — Scientific Deep Dive for NXP900 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.